Polarization of T lymphocytes is regulated by mesenchymal stem cells in NZBWF1 and BALB/c mice

International Journal of Molecular Sciences

Volumn 8, Issue 5, 2007, Pages 455-469

  Sun, Lingyun ^a   Liang, Jun ^a   Li, Hui ^b   Hou, Yayi ^c  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

^c NANJING UNIVERSITY   (China)

Author keywords

BALB c mice; Mesenchymal stem cells (MSCs); NZBWF1 mice; Systemic lupus erythematosus (SLE); T lymphocytes; Th1 Th2

Indexed keywords

CD3 ANTIGEN; CYTOKINE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; NYLON; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CELL STRAIN; CELL STRUCTURE; CELL SURFACE; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; IMMUNOREGULATION; MALE; MESENCHYMAL STEM CELL; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRAIN DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; WESTERN BLOTTING; WOOL;

MUS;

EID: 34249906991     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/i8050455     Document Type: Article

References (47)

1. Wofsy, D.; Seaman, W.E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J. Exp. Med. 1985, 161, 378-391.
2. Wofsy, D. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J. Immunol. 1986, 136, 4554-4560.
3. Funauchi, M.; Ikoma, S.; Enomoto, H.; Horiuchi, A. Decreased Th1-like and increased Th-2 like cells in systemic lupus erythematosus. Scand. J. Rheumatol. 1998, 27, 219-224.
4. Takahashi, S.; Fossati, L.; Iwamoto, M.; Merino, R.; Motta, R.; Kobayakawa, T. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J. Clin. Invest. 1996, 97, 1597-1604.
5. Ikehara, S. Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment. Int. J. Mol. Med. 1998, 1, 5-16.
6. Frassoni, F.; Labopin, M.; Bacigalupo, A.; Gluckman, E.; Rocha, V.; Bruno, B. Expanded mesenchymal stem cells (MSC), coinfused with HLA identical hematopoietic stem cell transplants, reduce acute and chronic graft-vs-host disease: a matched pair analysis. Bone Marrow Transpl. 2002, 29, S2.
7. Lazarus, H.; Curtin, P.; Devine. S.; McCarthy, P.; Holland, K.; Moseley, A. Role of mesenchymal stem cells (MSC) in allogeneic transplantation: Early phase I clinical results. Blood 2000, 96, 392A.
8. Koc, O.N.; Gerson, S.L.; Phillips, G.L.; Cooper, B.W.; Kutteh, L. Autologous CD34+ cell transplantation for patients with advanced lymphoma: Effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment. Bone Marrow Transpl. 1998, 21, 337-343.
9. Brandt, J.E.; Galy, A.H.; Luens, K.M.; Travis, M.; Young, J.; Tong, J. Bone marrow repopulation by human marrow stem cells after long-term expansion culture on a porcine endothelial cell line. Exp. Hematol. 1998, 26, 950-961.
10. Lazarus, H.M.; Haynesworth, S.E.; Gerson, S.L.; Rosenthal, N.S.; Caplan, A.I. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transpl. 1995, 16, 557-564.
11. Ikehara, S. New strategies for allogeneic BMT. Bone Marrow Transpl. 2003, 32, S73-75.
12. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 143-147.
13. Deans, R.J.; Moseley, A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol. 2000, 28, 875-884.
14. Kopen, G.C.; Prockop, D.J.; Phinney, D.G. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc. Natl. Acad. Sci. USA 1999, 96, 10711-10716.
15. Pereira, R.F.; O'Hara, M.D.; Laptev, A.V.; Halford, K.W.; Pollard, M.D.; Class, R. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc. Natl. Acad. Sci. USA 1998, 95, 1142-1147.
16. Toma, C.; Pittenger, M.F.; Cahill, K.S.; Byrne, B.J.; Kessler, P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002, 105, 93-98.
17. Le Blanc, K.; Tammikm C.; Rosendahl, K.; Zetterberg, E.; Ringden, O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 2003, 31, 890-896.
18. McIntosh, K.; Bartholomew, A. Stromal cell modulation of the immune system. Graft 2000, 3, 324-328.
19. Majumdar, M.K.; Keane-Moore, M.; Buyaner, D.; Hardy, W.B.; Moorman, M.A.; Mcintosh, K.R. Characterization and functionality of cell surface molecules on human mesencymal stem cells. J. Biomed. Sci. 2003, 10, 228-241.
20. Bartholomew, A.; Sturgeon, C.; Siatskas, M.; Ferrer, K.; McIntosh, K.; Patil, S. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 2002, 30, 42-48.
21. Potian, J.A.; Aviv, H.; Ponzio, N.M.; Harrison, J.S.; Rameshwar, P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recallantigens. J. Immunol. 2003, 171, 3426-3434.
22. Di Nicola, M.; Carlo-Stella, C.; Magni, M.; Milanesi, M.; Longoni, P.D.; Matteucci, P. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99, 3838-3843.
23. Le Blanc, K.; Rasmusson, I.; Gotherstrom, C.; Seidel, C.; Sundberg, B.; Sundin, M. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand. J. Immunol. 2004, 60, 307-315.
24. Corna, D.; Morigi, M.; Facchinetti, D.; Bertani, T.; Zoja, C.; Remuzzi, G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int. 1997, 51, 1583-1589.
25. Shirai, T.; Hirose, S.; Sekigawa, I.; Sato, H. Genetic and cellular basis of anti-DNA antibody synthesis in systemic lupus erythematosus of New Zealand mice. J. Rheumatol. 1987, 13, 11-20.
26. Haynesworth, S.E.; Baber, M.A.; Caplan, A.I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J. Cell Physiol. 1996, 166, 585-592.
27. Goshima, J.; Goldberg, V.M.; Caplan, A.I. The osteogenic potential of culture-expanded rat marrow mesenchymal cells assayed in vivo in calcium phosphate ceramic blocks. Clin. Orthop. 1991, 269, 298-311.
28. Pittenger, M.F.; Mackay, A.M.; Beck, S.C. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284,143-147.
29. Stute, N.; Holtz, K.; Bubenheim, M.; Langea, C.; Blake, F.; Zander, A.R. Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp. Hematol. 2004, 32, 1212-1215.
30. Szabo, S.; Kim, S.T.; Costa, L.G.; Zhang, X.; Fathman, C.G.; Glimcher, L. A novel transcription factor, T-bet, directs Th1 lineagecommitment. Cell 2000, 100, 655-659.
31. Pai, S.Y.; Truitt, M.L.; Ho, I.C. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. Proc. Natl. Acad. Sci. USA 2004, 101, 1993-1998.
32. Chakir, H.; Wang, H.; Lefebvre, D.E.; Webb, J.; Scott, F.W. T-bet /GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J. Immunol. Methods 2003, 278, 157-169.
33. Krampera, M.; Glennie, S.; Dyson. J.; Scott, D.; Laylor, R. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101, 3722-3729.
34. Djouad, F.; Plence, P.; Bony, C.; Tropel, P.; Apparailly, F.; Sany, J. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102, 3837-3844.
35. Deng, W.; Han, Q.; Liao, L. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell. Biol. 2005, 2, 458-463.
36. Rasmusson, I.; Ringden, O.; Sundberg, B.; Le Blanc, K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell. Res. 2005, 305, 33-41.
37. Zappia, E.; Casazza, S.; Pedemonte, E.; Benvenuto, F.; Bonanni, I.; Gerdoni, E. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106, 1755-1761.
38. Tse, W.T.; Pendleton, J.D.; Beyer, W.M.; Egalka, M.C.; Guinan, E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75, 389-397.
39. Plumas, J.; Chaperot, L.; Richard, M.J.; Molens, J.P.; Bensa, J.C.; Favrot, M.C. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005, 19, 1597-1604.
40. Le Blanc, K.; Ringden, O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood Marrow Tr. 2005, 11, 321-334.
41. Richaud-patin, Y.; Alcocer-Varela, J.; Llorente, L. High levels of TH2 cytokine gene expression in systemic lupus erythematosus. Rev. Invest. Clin. 1995, 47, 267-272.
42. Horwitz, D.A.; Gray, J.D.; Behrendsen, S.C.; Kubin, M.; Rengaraju, M.; Ohtsuka, K. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 1998, 41, 838-844.
43. Chen, Y.C.; Ye, Y.L.; Chiang, B.L. Establishment and characterization of cloned CD4-CD8- αβ-T cell receptor (TCR) -bearing autoreactive T cells from autoimmune NZBxNZWF1 mice. Clin. Exp. Immunol. 1997, 108, 52-57.
44. Aringer, M.; Zimmermann, C.; Graninger, W.B.; Petera, P.; Steiner, G.; Ulrich, W.; Smolen, J.S. TNF-α is an essential mediator in lupus nephritis. Arthritis Rheum. 2002, 46, 3418-3419.
45. Gabay, C.; Cakir, N.; Moral, F.; Roux-Lombard, P.; Meyer, O.; Dayer, J.M. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J. Rheumatol. 1997, 24, 303-308.
46. Al-Janadi, M.; Al-Balla, S.; Al-Dalaan, A.; Raziuddin, S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J. Clin. Immunol. 1993, 13, 58-67.
47. El-Badri, N.S.; Pascual, C.; Ferrari, A.; Maheshwari, A. Abnormalities of stromal cells in autoimmune systemic lupus murine model. Blood 2004, 104, 364A.